This year, we’re working on developing medicines targeting the circuits in the brain that control feeding behavior. Our platform is based on new IP in melanocortin neurobiology that could treat devastating psychiatric eating disorders such as anorexia nervosa and offer adjuvant treatments for obesity and diabetes.
The platform was co-founded by Dr. Roger Cone (Scientific Advisor) and Dan Housman (CEO) to develop bioactive molecules targeting these pathways discovered in Dr. Cone’s laboratory at the University of Michigan. This year, Dan Housman will join the The Incubator mentoring team and help guide the assessment of therapeutic and commercial strategies. We will create product profile sheets, build a business plan and assemble a pitch deck for potential investors.
See our schedule below: